, id,cid,dsn,cmpdname,srccmpd,srccmpdname,srccmpdurl,srctarget,srctargetname,srctargeturl,protacxn,protname,geneid,genename,taxid,taxname,action,actname,actvalue,evids,evurls,pmids,dois,citations
0,72552,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,8498,Potassium channel subfamily K member 2,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=8498,O95069,Potassium channel subfamily K member 2,3776.0,KCNK2,9606.0,Homo sapiens (human),,,,PMID:27346364|DOI:10.1111/cbdd.12810,https://www.ncbi.nlm.nih.gov/pubmed/27346364|https://doi.org/10.1111/cbdd.12810,27346364,10.1111/cbdd.12810,
1,86234,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA1,https://www.dgidb.org/genes/hgnc:6218,,,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,,,,,
2,86915,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNC1,https://www.dgidb.org/genes/hgnc:6233,,,3746.0,KCNC1,9606.0,Homo sapiens (human),Blocker,,,,,,,
3,86916,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNG3,https://www.dgidb.org/genes/hgnc:18306,,,170850.0,KCNG3,9606.0,Homo sapiens (human),Blocker,,,,,,,
4,86917,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA2,https://www.dgidb.org/genes/hgnc:6220,,,3737.0,KCNA2,9606.0,Homo sapiens (human),Blocker,,,,,,,
5,86918,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNB1,https://www.dgidb.org/genes/hgnc:6231,,,3745.0,KCNB1,9606.0,Homo sapiens (human),Blocker,,,,,,,
6,86919,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNG4,https://www.dgidb.org/genes/hgnc:19697,,,93107.0,KCNG4,9606.0,Homo sapiens (human),Blocker,,,,,,,
7,86920,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNC3,https://www.dgidb.org/genes/hgnc:6235,,,3748.0,KCNC3,9606.0,Homo sapiens (human),Blocker,,,,,,,
8,86921,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH5,https://www.dgidb.org/genes/hgnc:6254,,,27133.0,KCNH5,9606.0,Homo sapiens (human),Blocker,,,,,,,
9,86922,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNB2,https://www.dgidb.org/genes/hgnc:6232,,,9312.0,KCNB2,9606.0,Homo sapiens (human),Blocker,,,,,,,
10,86923,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH3,https://www.dgidb.org/genes/hgnc:6252,,,23416.0,KCNH3,9606.0,Homo sapiens (human),Blocker,,,,,,,
11,86924,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNG1,https://www.dgidb.org/genes/hgnc:6248,,,3755.0,KCNG1,9606.0,Homo sapiens (human),Blocker,,,,,,,
12,86925,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNC2,https://www.dgidb.org/genes/hgnc:6234,,,3747.0,KCNC2,9606.0,Homo sapiens (human),Blocker,,,,,,,
13,106121,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA3,https://www.dgidb.org/genes/hgnc:6221,,,3738.0,KCNA3,9606.0,Homo sapiens (human),Blocker,,,,,,,
14,106122,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNC4,https://www.dgidb.org/genes/hgnc:6236,,,3749.0,KCNC4,9606.0,Homo sapiens (human),Blocker,,,,,,,
15,106123,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNQ3,https://www.dgidb.org/genes/hgnc:6297,,,3786.0,KCNQ3,9606.0,Homo sapiens (human),Blocker,,,,,,,
16,106206,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNQ2,https://www.dgidb.org/genes/hgnc:6296,,,3785.0,KCNQ2,9606.0,Homo sapiens (human),Blocker,,,,,,,
17,106207,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNV2,https://www.dgidb.org/genes/hgnc:19698,,,169522.0,KCNV2,9606.0,Homo sapiens (human),Blocker,,,,,,,
18,106208,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCND2,https://www.dgidb.org/genes/hgnc:6238,,,3751.0,KCND2,9606.0,Homo sapiens (human),Blocker,,,,,,,
19,106209,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH6,https://www.dgidb.org/genes/hgnc:18862,,,81033.0,KCNH6,9606.0,Homo sapiens (human),Blocker,,,,,,,
20,106210,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNG2,https://www.dgidb.org/genes/hgnc:6249,,,26251.0,KCNG2,9606.0,Homo sapiens (human),Blocker,,,,,,,
21,106211,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNS1,https://www.dgidb.org/genes/hgnc:6300,,,3787.0,KCNS1,9606.0,Homo sapiens (human),Blocker,,,,,,,
22,106212,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCND1,https://www.dgidb.org/genes/hgnc:6237,,,3750.0,KCND1,9606.0,Homo sapiens (human),Blocker,,,,,,,
23,106325,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCND3,https://www.dgidb.org/genes/hgnc:6239,,,3752.0,KCND3,9606.0,Homo sapiens (human),Blocker,,,,,,,
24,106326,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNQ4,https://www.dgidb.org/genes/hgnc:6298,,,9132.0,KCNQ4,9606.0,Homo sapiens (human),Blocker,,,,,,,
25,106327,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNS2,https://www.dgidb.org/genes/hgnc:6301,,,3788.0,KCNS2,9606.0,Homo sapiens (human),Blocker,,,,,,,
26,106328,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH4,https://www.dgidb.org/genes/hgnc:6253,,,23415.0,KCNH4,9606.0,Homo sapiens (human),Blocker,,,,,,,
27,106329,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004716,Potassium voltage-gated channel subfamily A member 3,http://www.t3db.ca/biodb/bio_entities/BE0004716,P22001,Potassium voltage-gated channel subfamily A member 3,3738.0,KCNA3,9606.0,Homo sapiens (human),,,,PMID:16472864|PMID:15084131,https://www.ncbi.nlm.nih.gov/pubmed/16472864|https://www.ncbi.nlm.nih.gov/pubmed/15084131,16472864|15084131,,
28,106330,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0000781,Potassium voltage-gated channel subfamily A member 1,http://www.t3db.ca/biodb/bio_entities/BE0000781,Q09470,Potassium voltage-gated channel subfamily A member 1,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
29,106331,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004720,Potassium voltage-gated channel subfamily A member 10,http://www.t3db.ca/biodb/bio_entities/BE0004720,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
30,106332,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004715,Potassium voltage-gated channel subfamily A member 2,http://www.t3db.ca/biodb/bio_entities/BE0004715,P16389,Potassium voltage-gated channel subfamily A member 2,3737.0,KCNA2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
31,106333,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004502,Potassium voltage-gated channel subfamily A member 4,http://www.t3db.ca/biodb/bio_entities/BE0004502,P22459,Potassium voltage-gated channel subfamily A member 4,3739.0,KCNA4,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
32,106334,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004717,Potassium voltage-gated channel subfamily A member 5,http://www.t3db.ca/biodb/bio_entities/BE0004717,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
33,106335,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004718,Potassium voltage-gated channel subfamily A member 6,http://www.t3db.ca/biodb/bio_entities/BE0004718,P17658,Potassium voltage-gated channel subfamily A member 6,3742.0,KCNA6,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
34,106336,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004719,Potassium voltage-gated channel subfamily A member 7,http://www.t3db.ca/biodb/bio_entities/BE0004719,Q96RP8,Potassium voltage-gated channel subfamily A member 7,3743.0,KCNA7,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
35,106527,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004721,Potassium voltage-gated channel subfamily B member 1,http://www.t3db.ca/biodb/bio_entities/BE0004721,Q14721,Potassium voltage-gated channel subfamily B member 1,3745.0,KCNB1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
36,106528,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004722,Potassium voltage-gated channel subfamily B member 2,http://www.t3db.ca/biodb/bio_entities/BE0004722,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
37,106529,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004723,Potassium voltage-gated channel subfamily C member 1,http://www.t3db.ca/biodb/bio_entities/BE0004723,P48547,Potassium voltage-gated channel subfamily C member 1,3746.0,KCNC1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
38,106530,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004724,Potassium voltage-gated channel subfamily C member 2,http://www.t3db.ca/biodb/bio_entities/BE0004724,Q96PR1,Potassium voltage-gated channel subfamily C member 2,3747.0,KCNC2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
39,106531,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004725,Potassium voltage-gated channel subfamily C member 3,http://www.t3db.ca/biodb/bio_entities/BE0004725,Q14003,Potassium voltage-gated channel subfamily C member 3,3748.0,KCNC3,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
40,106532,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004726,Potassium voltage-gated channel subfamily D member 1,http://www.t3db.ca/biodb/bio_entities/BE0004726,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
41,106533,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0003603,Potassium voltage-gated channel subfamily D member 2,http://www.t3db.ca/biodb/bio_entities/BE0003603,Q9NZV8,Potassium voltage-gated channel subfamily D member 2,3751.0,KCND2,9606.0,Homo sapiens (human),,,,PMID:23184313,https://www.ncbi.nlm.nih.gov/pubmed/23184313,23184313,,
42,106534,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0003604,Potassium voltage-gated channel subfamily D member 3,http://www.t3db.ca/biodb/bio_entities/BE0003604,Q9UK17,Potassium voltage-gated channel subfamily D member 3,3752.0,KCND3,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
43,106535,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0000090,Potassium voltage-gated channel subfamily H member 2,http://www.t3db.ca/biodb/bio_entities/BE0000090,Q12809,Potassium voltage-gated channel subfamily H member 2,3757.0,KCNH2,9606.0,Homo sapiens (human),,,,PMID:15324906,https://www.ncbi.nlm.nih.gov/pubmed/15324906,15324906,,
44,137047,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,508,TRPV2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=508,Q9WTR1,Transient receptor potential cation channel subfamily V member 2,22368.0,Trpv2,10090.0,Mus musculus (house mouse),Inhibition,,6.2,PMID:17673572,https://www.ncbi.nlm.nih.gov/pubmed/17673572,17673572,,
45,137048,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,541,Kv1.4,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=541,P15385,Potassium voltage-gated channel subfamily A member 4,25469.0,Kcna4,10116.0,Rattus norvegicus (Norway rat),,pIC50,1.9,PMID:2555158,https://www.ncbi.nlm.nih.gov/pubmed/2555158,2555158,,
46,137049,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,542,Kv1.5,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),Pore blocker,pKd,3.6,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
47,137050,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,546,Kv2.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=546,P15387,Potassium voltage-gated channel subfamily B member 1,25736.0,Kcnb1,10116.0,Rattus norvegicus (Norway rat),Pore blocker,pIC50,3.3,PMID:8301258,https://www.ncbi.nlm.nih.gov/pubmed/8301258,8301258,,
48,137051,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,547,Kv2.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=547,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),,pIC50,2.8,PMID:9612272,https://www.ncbi.nlm.nih.gov/pubmed/9612272,9612272,,
49,137052,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,544,Kv1.7,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=544,Q17ST2,Potassium voltage-gated channel subfamily A member 7,16495.0,Kcna7,10090.0,Mus musculus (house mouse),,pIC50,3.6,PMID:9488722,https://www.ncbi.nlm.nih.gov/pubmed/9488722,9488722,,
50,137053,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,544,Kv1.7,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=544,Q17ST2,Potassium voltage-gated channel subfamily A member 7,16495.0,Kcna7,10090.0,Mus musculus (house mouse),Pore blocker,pKd,3.8,PMID:16801386,https://www.ncbi.nlm.nih.gov/pubmed/16801386,16801386,,
51,137054,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,545,Kv1.8,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=545,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),,pIC50,2.8,PMID:10836990,https://www.ncbi.nlm.nih.gov/pubmed/10836990,10836990,,
52,137055,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,539,Kv1.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=539,P63142,Potassium voltage-gated channel subfamily A member 2,25468.0,Kcna2,10116.0,Rattus norvegicus (Norway rat),Pore blocker,pKd,3.2,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
53,137248,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,550,Kv3.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550,Q01956,Potassium voltage-gated channel subfamily C member 3,,,10116.0,Rattus norvegicus (Norway rat),,pIC50,2.9,PMID:1381835,https://www.ncbi.nlm.nih.gov/pubmed/1381835,1381835,,
54,137249,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,550,Kv3.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550,,,117101.0,Kcnc3,10116.0,Rattus norvegicus (Norway rat),,pIC50,2.9,PMID:1381835,https://www.ncbi.nlm.nih.gov/pubmed/1381835,1381835,,
55,137250,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,552,Kv4.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=552,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),,pIC50,2,PMID:10729221,https://www.ncbi.nlm.nih.gov/pubmed/10729221,10729221,,
56,137251,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,552,Kv4.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=552,Q03719,Potassium voltage-gated channel subfamily D member 1,16506.0,Kcnd1,10090.0,Mus musculus (house mouse),,pIC50,2,PMID:11805342,https://www.ncbi.nlm.nih.gov/pubmed/11805342,11805342,,
57,137252,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,553,Kv4.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=553,Q9Z0V2,Potassium voltage-gated channel subfamily D member 2,16508.0,Kcnd2,10090.0,Mus musculus (house mouse),,pIC50,2.3,PMID:16317109,https://www.ncbi.nlm.nih.gov/pubmed/16317109,16317109,,
58,137253,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,548,Kv3.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=548,P15388,Potassium voltage-gated channel subfamily C member 1,16502.0,Kcnc1,10090.0,Mus musculus (house mouse),,pIC50,4.5,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
59,137254,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,549,Kv3.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=549,P22462,Potassium voltage-gated channel subfamily C member 2,246153.0,Kcnc2,10116.0,Rattus norvegicus (Norway rat),,pIC50,4.6,PMID:11790809,https://www.ncbi.nlm.nih.gov/pubmed/11790809,11790809,,
60,137255,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,554,Kv4.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=554,Q9Z0V1,Potassium voltage-gated channel subfamily D member 3,56543.0,Kcnd3,10090.0,Mus musculus (house mouse),,pIC50,2.4,PMID:17016508,https://www.ncbi.nlm.nih.gov/pubmed/17016508,17016508,,
61,137256,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,SLC22A2,https://www.dgidb.org/genes/hgnc:10966,,,6582.0,SLC22A2,9606.0,Homo sapiens (human),,,,,,,,
62,137257,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0000781,Potassium voltage-gated channel subfamily A member 1,https://www.drugbank.ca/bio_entities/BE0000781,Q09470,Potassium voltage-gated channel subfamily A member 1,3736.0,KCNA1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
63,137258,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004715,Potassium voltage-gated channel subfamily A member 2,https://www.drugbank.ca/bio_entities/BE0004715,P16389,Potassium voltage-gated channel subfamily A member 2,3737.0,KCNA2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
64,137437,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004716,Potassium voltage-gated channel subfamily A member 3,https://www.drugbank.ca/bio_entities/BE0004716,P22001,Potassium voltage-gated channel subfamily A member 3,3738.0,KCNA3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
65,137438,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004502,Potassium voltage-gated channel subfamily A member 4,https://www.drugbank.ca/bio_entities/BE0004502,P22459,Potassium voltage-gated channel subfamily A member 4,3739.0,KCNA4,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
66,137439,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004717,Potassium voltage-gated channel subfamily A member 5,https://www.drugbank.ca/bio_entities/BE0004717,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
67,137440,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004718,Potassium voltage-gated channel subfamily A member 6,https://www.drugbank.ca/bio_entities/BE0004718,P17658,Potassium voltage-gated channel subfamily A member 6,3742.0,KCNA6,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
68,137441,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004719,Potassium voltage-gated channel subfamily A member 7,https://www.drugbank.ca/bio_entities/BE0004719,Q96RP8,Potassium voltage-gated channel subfamily A member 7,3743.0,KCNA7,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
69,137442,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004720,Potassium voltage-gated channel subfamily A member 10,https://www.drugbank.ca/bio_entities/BE0004720,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
70,137443,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004721,Potassium voltage-gated channel subfamily B member 1,https://www.drugbank.ca/bio_entities/BE0004721,Q14721,Potassium voltage-gated channel subfamily B member 1,3745.0,KCNB1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
71,137444,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004722,Potassium voltage-gated channel subfamily B member 2,https://www.drugbank.ca/bio_entities/BE0004722,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
72,137445,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004723,Potassium voltage-gated channel subfamily C member 1,https://www.drugbank.ca/bio_entities/BE0004723,P48547,Potassium voltage-gated channel subfamily C member 1,3746.0,KCNC1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
73,137446,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004724,Potassium voltage-gated channel subfamily C member 2,https://www.drugbank.ca/bio_entities/BE0004724,Q96PR1,Potassium voltage-gated channel subfamily C member 2,3747.0,KCNC2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
74,137647,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004725,Potassium voltage-gated channel subfamily C member 3,https://www.drugbank.ca/bio_entities/BE0004725,Q14003,Potassium voltage-gated channel subfamily C member 3,3748.0,KCNC3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
75,137648,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004726,Potassium voltage-gated channel subfamily D member 1,https://www.drugbank.ca/bio_entities/BE0004726,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
76,137649,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003603,Potassium voltage-gated channel subfamily D member 2,https://www.drugbank.ca/bio_entities/BE0003603,Q9NZV8,Potassium voltage-gated channel subfamily D member 2,3751.0,KCND2,9606.0,Homo sapiens (human),Antagonist,,,PMID:23184313,https://www.ncbi.nlm.nih.gov/pubmed/23184313,23184313,,
77,137650,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003604,Potassium voltage-gated channel subfamily D member 3,https://www.drugbank.ca/bio_entities/BE0003604,Q9UK17,Potassium voltage-gated channel subfamily D member 3,3752.0,KCND3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
78,137651,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003533,Cytochrome P450 2E1,https://www.drugbank.ca/bio_entities/BE0003533,P05181,Cytochrome P450 2E1,1571.0,CYP2E1,9606.0,Homo sapiens (human),Substrate,,,PMID:22764324,https://www.ncbi.nlm.nih.gov/pubmed/22764324,22764324,,
79,137652,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003647,Solute carrier family 22 member 2,https://www.drugbank.ca/bio_entities/BE0003647,O15244,Solute carrier family 22 member 2,6582.0,SLC22A2,9606.0,Homo sapiens (human),Substrate,,,,,,,
80,137653,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,147,ADRA1B,https://ctdbase.org/detail.go?type=gene&acc=147,,,147.0,ADRA1B,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to phenylephrine],,,PMID:18480251,https://www.ncbi.nlm.nih.gov/pubmed/18480251,18480251,,
81,137654,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,581,BAX,https://ctdbase.org/detail.go?type=gene&acc=581,,,581.0,BAX,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of BAX mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
82,137655,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,329,BIRC2,https://ctdbase.org/detail.go?type=gene&acc=329,,,329.0,BIRC2,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of BIRC2 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
83,137656,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,330,BIRC3,https://ctdbase.org/detail.go?type=gene&acc=330,,,330.0,BIRC3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of BIRC3 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
84,137838,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,90427,BMF,https://ctdbase.org/detail.go?type=gene&acc=90427,,,90427.0,BMF,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of BMF mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
85,137839,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,54991,C1ORF159,https://ctdbase.org/detail.go?type=gene&acc=54991,,,54991.0,C1orf159,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of C1ORF159 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
86,137840,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,836,CASP3,https://ctdbase.org/detail.go?type=gene&acc=836,,,836.0,CASP3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP3 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
87,137841,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,840,CASP7,https://ctdbase.org/detail.go?type=gene&acc=840,,,840.0,CASP7,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP7 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
88,137842,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,842,CASP9,https://ctdbase.org/detail.go?type=gene&acc=842,,,842.0,CASP9,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP9 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
89,137843,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,2906,GRIN2D,https://ctdbase.org/detail.go?type=gene&acc=2906,,,2906.0,GRIN2D,10090.0,Mus musculus (house mouse),[bicuculline co-treated with 4-aminopyridine] results in decreased expression of GRIN2D protein,,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
90,137844,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,10014,HDAC5,https://ctdbase.org/detail.go?type=gene&acc=10014,,,10014.0,HDAC5,10116.0,Rattus norvegicus (Norway rat),[bicuculline co-treated with 4-aminopyridine] affects the localization of HDAC5 protein,,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
91,137845,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,57338,JPH3,https://ctdbase.org/detail.go?type=gene&acc=57338,,,57338.0,JPH3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of JPH3 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
92,137846,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3744,KCNA10,https://ctdbase.org/detail.go?type=gene&acc=3744,,,3744.0,KCNA10,9606.0,Homo sapiens (human),4-aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of potassium],,,PMID:10836990,https://www.ncbi.nlm.nih.gov/pubmed/10836990,10836990,,
93,137847,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3741,KCNA5,https://ctdbase.org/detail.go?type=gene&acc=3741,,,3741.0,KCNA5,9606.0,Homo sapiens (human),4-aminopyridine results in decreased activity of KCNA5 protein,,,PMID:23261645,https://www.ncbi.nlm.nih.gov/pubmed/23261645,23261645,,
94,137848,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3752,KCND3,https://ctdbase.org/detail.go?type=gene&acc=3752,,,3752.0,KCND3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of KCND3 mrna|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased expression of KCND3 mrna],,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
95,138046,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3757,KCNH2,https://ctdbase.org/detail.go?type=gene&acc=3757,,,3757.0,KCNH2,9606.0,Homo sapiens (human),4-aminopyridine results in decreased activity of KCNH2 protein,,,PMID:19915712,https://www.ncbi.nlm.nih.gov/pubmed/19915712,19915712,,
96,138047,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,30820,KCNIP1,https://ctdbase.org/detail.go?type=gene&acc=30820,,,30820.0,KCNIP1,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of KCNIP1 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
97,138048,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,30820,KCNIP1,https://ctdbase.org/detail.go?type=gene&acc=30820,,,30820.0,KCNIP1,10116.0,Rattus norvegicus (Norway rat),KCNIP1 mRNA promotes the reaction [4-aminopyridine results in increased abundance of gamma-aminobutyric acid]|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased expression of GAD2 mrna]|4-aminopyridine results in increased expression of KCNIP1 mrna|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased expression of KCND3 mrna],,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
98,138049,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,4099,MAG,https://ctdbase.org/detail.go?type=gene&acc=4099,,,4099.0,MAG,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of MAG mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
99,138050,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,84557,MAP1LC3A,https://ctdbase.org/detail.go?type=gene&acc=84557,,,84557.0,MAP1LC3A,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of MAP1LC3A mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
100,138051,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10090.0,Mus musculus (house mouse),[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein|dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein],,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
101,138052,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),Hispidulin inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein]|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein],,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
102,138053,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),Typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK1 protein]|[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK1 protein,,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
103,138054,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased phosphorylation of MAPK1 protein,,,PMID:22759588|PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/22759588|https://www.ncbi.nlm.nih.gov/pubmed/28132918,22759588|28132918,,
104,138249,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),Ciproxifan inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein],,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
105,138250,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10090.0,Mus musculus (house mouse),[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein|dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein],,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
106,138251,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Hispidulin inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein]|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein],,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
107,138252,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK3 protein]|[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK3 protein,,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
108,138253,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased phosphorylation of MAPK3 protein,,,PMID:22759588|PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/22759588|https://www.ncbi.nlm.nih.gov/pubmed/28132918,22759588|28132918,,
109,138254,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Ciproxifan inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein],,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
110,138255,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,9612,NCOR2,https://ctdbase.org/detail.go?type=gene&acc=9612,,,9612.0,NCOR2,10116.0,Rattus norvegicus (Norway rat),KN 62 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein]|sto 609 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein]|[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein],,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
111,138256,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,258881,OR10J3B,https://ctdbase.org/detail.go?type=gene&acc=258881,,,258881.0,Or10j3b,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of OR10J3B mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
112,138257,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5327,PLAT,https://ctdbase.org/detail.go?type=gene&acc=5327,,,5327.0,PLAT,9606.0,Homo sapiens (human),[bicuculline co-treated with 4-aminopyridine co-treated with dizocilpine maleate] results in decreased susceptibility to PLAT protein,,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
113,138454,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5566,PRKACA,https://ctdbase.org/detail.go?type=gene&acc=5566,,,5566.0,PRKACA,10116.0,Rattus norvegicus (Norway rat),Lappaconitine inhibits the reaction [4-aminopyridine results in increased phosphorylation of PRKACA protein]|4-aminopyridine results in increased phosphorylation of PRKACA protein,,,PMID:35643327,https://www.ncbi.nlm.nih.gov/pubmed/35643327,35643327,,
114,138455,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5914,RARA,https://ctdbase.org/detail.go?type=gene&acc=5914,,,5914.0,RARA,10116.0,Rattus norvegicus (Norway rat),STO 609 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]|dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]|[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]|kn 62 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]],,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
115,138456,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,338324,S100A7A,https://ctdbase.org/detail.go?type=gene&acc=338324,,,338324.0,S100A7A,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of S100A7A mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
116,138457,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6616,SNAP25,https://ctdbase.org/detail.go?type=gene&acc=6616,,,6616.0,SNAP25,10116.0,Rattus norvegicus (Norway rat),Lappaconitine inhibits the reaction [4-aminopyridine results in increased phosphorylation of SNAP25 protein]|4-aminopyridine results in increased phosphorylation of SNAP25 protein,,,PMID:35643327,https://www.ncbi.nlm.nih.gov/pubmed/35643327,35643327,,
117,138458,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10090.0,Mus musculus (house mouse),SYN1 protein affects the susceptibility to 4-aminopyridine,,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
118,138459,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10090.0,Mus musculus (house mouse),Ciproxifan inhibits the reaction [4-aminopyridine results in increased expression of SYN1 protein modified form]|4-aminopyridine results in increased expression of SYN1 protein modified form|syn1 results in increased susceptibility to 4-aminopyridine,,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
119,138460,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10116.0,Rattus norvegicus (Norway rat),Typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of SYN1 protein]|[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of SYN1 protein,,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
120,138461,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,7186,TRAF2,https://ctdbase.org/detail.go?type=gene&acc=7186,,,7186.0,TRAF2,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of TRAF2 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
121,161890,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH1,https://www.dgidb.org/genes/hgnc:6250,,,3756.0,KCNH1,9606.0,Homo sapiens (human),Blocker,,,,,,,
122,161891,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA7,https://www.dgidb.org/genes/hgnc:6226,,,3743.0,KCNA7,9606.0,Homo sapiens (human),Blocker,,,,,,,
123,161892,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH7,https://www.dgidb.org/genes/hgnc:18863,,,90134.0,KCNH7,9606.0,Homo sapiens (human),Blocker,,,,,,,
124,161893,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNV1,https://www.dgidb.org/genes/hgnc:18861,,,27012.0,KCNV1,9606.0,Homo sapiens (human),Blocker,,,,,,,
125,161894,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNQ1,https://www.dgidb.org/genes/hgnc:6294,,,3784.0,KCNQ1,9606.0,Homo sapiens (human),Blocker,,,,,,,
126,179662,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,959,CD40LG,https://ctdbase.org/detail.go?type=gene&acc=959,,,959.0,CD40LG,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CD40LG mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
127,180009,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,1508,CTSB,https://ctdbase.org/detail.go?type=gene&acc=1508,,,1508.0,CTSB,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CTSB mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
128,180010,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,10570,DPYSL4,https://ctdbase.org/detail.go?type=gene&acc=10570,,,10570.0,DPYSL4,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of DPYSL4 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
129,180011,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,2572,GAD2,https://ctdbase.org/detail.go?type=gene&acc=2572,,,2572.0,GAD2,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of GAD2 mrna|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased expression of GAD2 mrna],,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
130,180012,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,11227,GALNT5,https://ctdbase.org/detail.go?type=gene&acc=11227,,,11227.0,GALNT5,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of GALNT5 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
131,186787,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,1043,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1043,P37136,Acetylcholinesterase,83817.0,Ache,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),>500000,PMID:10632067|DOI:10.1016/s0968-0896(99)00178-9,https://www.ncbi.nlm.nih.gov/pubmed/10632067|https://doi.org/10.1016/s0968-0896(99)00178-9,10632067,10.1016/s0968-0896(99)00178-9,
132,186788,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,1044,Carboxylic ester hydrolase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1044,,,,,,,,IC50 (nM),>500000,PMID:10632067|DOI:10.1016/s0968-0896(99)00178-9,https://www.ncbi.nlm.nih.gov/pubmed/10632067|https://doi.org/10.1016/s0968-0896(99)00178-9,10632067,10.1016/s0968-0896(99)00178-9,
133,188703,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,958,CD40,https://ctdbase.org/detail.go?type=gene&acc=958,,,958.0,CD40,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CD40 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
134,188704,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA1,https://www.dgidb.org/genes/hgnc:6218,,,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,,,,,
135,188705,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,CALCA,https://www.dgidb.org/genes/hgnc:1437,,,796.0,CALCA,9606.0,Homo sapiens (human),,,,,,,,
136,211640,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA6,https://www.dgidb.org/genes/hgnc:6225,,,3742.0,KCNA6,9606.0,Homo sapiens (human),Blocker,,,,,,,
137,211641,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA10,https://www.dgidb.org/genes/hgnc:6219,,,3744.0,KCNA10,9606.0,Homo sapiens (human),Blocker,,,,,,,
138,211642,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA4,https://www.dgidb.org/genes/hgnc:6222,,,3739.0,KCNA4,9606.0,Homo sapiens (human),Blocker,,,,,,,
139,211828,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH2,https://www.dgidb.org/genes/hgnc:6251,,,3757.0,KCNH2,9606.0,Homo sapiens (human),Blocker,,,,,,,
140,211829,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA1,https://www.dgidb.org/genes/hgnc:6218,,,3736.0,KCNA1,9606.0,Homo sapiens (human),Blocker,,,,,,,
141,211830,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNA5,https://www.dgidb.org/genes/hgnc:6224,,,3741.0,KCNA5,9606.0,Homo sapiens (human),Blocker,,,,,,,
142,211831,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNS3,https://www.dgidb.org/genes/hgnc:6302,,,3790.0,KCNS3,9606.0,Homo sapiens (human),Blocker,,,,,,,
143,211832,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNH8,https://www.dgidb.org/genes/hgnc:18864,,,131096.0,KCNH8,9606.0,Homo sapiens (human),Blocker,,,,,,,
144,211833,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNF1,https://www.dgidb.org/genes/hgnc:6246,,,3754.0,KCNF1,9606.0,Homo sapiens (human),Blocker,,,,,,,
145,211834,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,443,Kir7.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=443,O60928,Inward rectifier potassium channel 13,3769.0,KCNJ13,9606.0,Homo sapiens (human),Antagonist,,1.6,PMID:9620703,https://www.ncbi.nlm.nih.gov/pubmed/9620703,9620703,,
146,211835,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,KCNQ5,https://www.dgidb.org/genes/hgnc:6299,,,56479.0,KCNQ5,9606.0,Homo sapiens (human),Blocker,,,,,,,
147,211836,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/rxcui:897018,,CYP2D6,https://www.dgidb.org/genes/hgnc:2625,,,1565.0,CYP2D6,9606.0,Homo sapiens (human),,,,,,,,
